通过在开放式域调整中进行超球加权对抗性学习来改善阿尔茨海默病诊断
Qiongmin Zhang1, Siyi Yu1, Yin Shi1
1College of Computer Science and Engineering, Chongqing University of Technology, Chongqing, 400054, China.
概括
这项研究引入了一种新的AI方法,用于使用脑MRI扫描来诊断阿尔茨海默病 (AD),即使使用各种扫描数据和未知的疾病,也提高了准确性. 在复杂的临床环境中,HWAL-OSDA模型实现了高诊断性能.
科学领域:
- 神经成像和人工智能的人工智能
- 医学图像分析 医学图像分析
- 机器学习用于医疗保健
背景情况:
- 阿尔茨海默氏病 (AD) 诊断依赖于磁共振成像 (MRI),但扫描器变异和未知的疾病挑战计算机辅助诊断 (CAD) 系统.
- 封闭的域适应方法与AD诊断的现实世界临床数据的多样性和复杂性作斗争.
- 现有的CAD模型往往错误地诊断了在培训数据中不包含的疾病,突出了对强大的开放式方法的需求.
研究的目的:
- 开发和评估一种新的基于高层加权对抗学习的开放集域适应 (HWAL-OSDA) 方法,用于准确诊断阿尔茨海默病.
- 解决MRI数据中的域位移问题,并提高模型区分已知的和未知的神经退行性疾病的能力.
- 提高CAD系统在多样化和开放的临床环境中的性能.
主要方法:
- 实现了基于voxel的3D特征提取和融合模块,用于全面的MRI空间特征捕获.
- 使用多尺度和双重注意力聚合块专注于对疾病敏感的大脑区域.
- 整合了超球变量自动编码器和基于球形角距离的损失,以改善特征表示和类分离性.
- 设计了一个加权对抗域适应模块,具有动态实例级加权 (韦布尔分布和),用于管理已知和未知样本传输.
主要成果:
- 在ADNI和PPMI数据集上,HWAL-OSDA方法实现了高平均准确率:94.2% (AD对CN对Unk),83.68% (MCI对CN对Unk) 和77.83% (AD对MCI对Unk).
- HWAL-OSDA显著超过了传统和最先进的开放集域适应 (OSDA) 方法.
- 该模型在处理域位移和分类未知的条件方面表现出有效性.
结论:
- 拟议的HWAL-OSDA方法为阿尔茨海默病诊断在具有挑战性的,开放的临床环境中提供了强大而准确的解决方案.
- 这种方法有效地处理域变异,并提高了用于神经退行性疾病的CAD系统的可靠性.
- HWAL-OSDA为开发针对AD和其他神经系统疾病的先进CAD系统提供了实用参考.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.8K
07:11Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
Published on: December 8, 2023
2.3K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
